Headache associated with cyclosporin in a patient with membranous glomerulonephritis;Cefalea asociada a ciclosporina en un paciente con glomerulonefritis membranosa

Farmacia Hospitalaria

Volumn 28, Issue 6, 2004, Pages 454-457

  Borrás Blasco, Joaquín ^a,b   Enriquez R ^a   Amoros Amoros F ^a   Navarro Ruiz, A ^a   Conesa Garcia V ^a   Gonzalez Delgado M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Adverse reaction; Cyclosporin; Headache

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN A; DIHYDROCODEINE; ERGOTAMINE DERIVATIVE; FUROSEMIDE; LOSARTAN; PIZOTIFEN; PROPRANOLOL; RANITIDINE; SIMVASTATIN; SUMATRIPTAN; TACROLIMUS; THROMBOXANE A2; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERTROPHY; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MEMBRANOUS GLOMERULONEPHRITIS; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE;

AGED; CYCLOSPORINE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HEADACHE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 13444270883     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Horton S, Resman-Targoff BH, Thompson DF. Use of cyclosporine in rheumatoid arthritis. Ann Pharmacother 1993; 27: 44-6.
2. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) in organ transplantation. Drugs 2001; 61: 1957-2016.
3. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996; 34: 515-9.
4. Philip AT, Gerson B. Toxicology and adverse effects of drugs used for immunosuppression in organ transplantation. Clin Lab Med 1998; 18: 755-65.
5. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995; 45: 1962-4.
6. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246: 339-46.
7. Reece DE, Frei-Lahr DA, Shepherd JD, Dorovini-Zis K, Gascoyne RD, Graeb DA, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 1991; 8: 393-401.
8. Rozen TD, Wijdicks EF, Hay JE. Treatment-refractory cyclosporine- associated headache: relief with conversion to FK-506. Neurology 1996; 47: 1347.
9. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 1987; 317: 861-6.
10. Gryn J, Goldberg J, Viner E. Propranolol for the treatment of cyclosporine-induced headaches. Bone Marrow Transplant 1992; 9: 211-2.
11. Fradin MS, Ellis CN, Voorhees JJ. Management of patients and side effects during cyclosporine therapy for cutaneous disorders. J Am Acad Dermatol 1990; 23: 1265-73.
12. Steiger MJ, Farrah T, Rolles K, Harvey P, Burroughs AK. Cyclosporin associated headache. J Neurol Neurosurg Psychiatry 1994; 57: 1258-9.
13. Maghrabi K, Bohlega S. Cyclosporine-induced migraine with severe vomiting causing loss of renal graft. Clin Neurol Neurosurg 1998; 100: 224-7.
14. Toung TJ, Bunke FJ, Grayson RF, Kontos GJ, Fraser CD Jr, Baumgartner WA, et al. Effects of cyclosporine on cerebral blood flow and metabolism in dogs. Transplantation 1992; 53: 1082-8.
15. Morris R. Modes of action of FK506, cyclosporin A, and rapamycin. Transplant Proc 1994; 26: 3272-5.
16. Christiansen I, Iversen HK, Olesen J. Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. Cephalalgia 2000; 20: 437-44.
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.